Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Appendix
Innovation: Clinical trials
Innovation: Pipeline overview
References
Abbreviations
Novartis is committed to driving consistent growth through 2030
and beyond
IM sales evolution
Illustrative, USD bn, % CAGR CC
+8%¹
38
39
35
49
>Median
(aspiration)
≥4%
42
2
3
2026 2030 >2030
1 2020-2026 |≥4%
Focused resources on key growth
brands and launches, upscaling next
generation engagement models
2 2026-2030 | >peer median
Double-down on internal pipeline
assets to unlock their full potential
and add complementary BD&L
3 >2030 |>peer median
Focused investments in technology
platforms while staying at the forefront of
innovation in small and large molecules
нн
2018
2019
2020
2021
1.6% in USD.
32 Investor Relations | Q1 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation